Effect of Rifampicin on The Pharmacokinetics of Selexipag, An Oral Prostacyclin Receptor Agonist, and Its Active Metabolite In Healthy Male Subjects

Methods This was an open-label, randomized, two-treatment, two-period, crossover study including 20 healthy male subjects. Concomitant administration of selexipag and multiple-dose rifampicin led to no relevant change in exposure to selexipag (geometric mean ratios [Treatment B/Treatment A] and 90%...

Full description

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 39; no. 8; p. e24
Main Authors Bruderer, S., Petersen-Sylla, M., Boehler, M., Remeňová, T., Halabi, A., Dingemanse, J.
Format Journal Article
LanguageEnglish
Published Bridgewater Elsevier Inc 01.08.2017
Elsevier Limited
Subjects
Internal Medicine
Medical Education
Pharmacokinetics
Prostacyclin
Rifampin
Online AccessGet full text

Cover

More Information
Summary:Methods This was an open-label, randomized, two-treatment, two-period, crossover study including 20 healthy male subjects. Concomitant administration of selexipag and multiple-dose rifampicin led to no relevant change in exposure to selexipag (geometric mean ratios [Treatment B/Treatment A] and 90% confidence intervals [CIs] for maximum plasma concentration (Cmax) and area under...
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2017.05.073